Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of
the European Myeloma Network (EMN)

Running head: Personalized therapy in MM: age and vulnerability

Antonio Palumbo,¹ Sara Bringhen,¹ Heinz Ludwig,² Meletios A. Dimopoulos,³ Joan Bladé,⁴ Maria V. Mateos,⁵ Laura Rosiñol,⁶ Mario Boccadoro,¹ Michele Cavo,⁷ Henk Lokhorst,⁸ Sonja Zweegman,⁹ Evangelos Terpos,³ Faith Davies,¹⁰ Christoph Driessen,¹¹ Peter Gimsing,¹² Martin Gramatzki,¹³ Roman Hajek,¹⁴ Hans E. Johnsen,¹⁵ Fernando Leal Da Costa,¹⁶ Orhan Sezer,¹⁷ Andrew Spencer,¹⁸ Meral Bekesac,¹⁹ Gareth Morgan,¹⁰ Hermann Einsele,²⁰ Jesus F. San Miguel,⁵ and Pieter Sonneveld²¹

¹Myeloma Unit, Division of Hematology, University of Torino, AOU S. Giovanni Battista, Torino, Italy; ²Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Vienna, Austria; ³Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra General Hospital, Athens, Greece; ⁴Department of Hematology, Hospital Clinic, Barcelona, Spain; ⁵Servicio de Hematología, Hospital Universitario de Salamanca, and CIC, IBMCC (USAL-CSIC), Salamanca, Spain; ⁶Hospital Clinic, Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; ⁷Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Bologna, Italy; ⁸Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands; ⁹Department of Hematology VU University Medical Center, Amsterdam, Netherlands; ¹⁰Institute of Cancer Research and Royal Marsden Hospital, London, UK; ¹¹Department of Oncology/Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland; ¹²Department of Haematology, University Hospital of Copenhagen at Rigshospitalet, Copenhagen, Denmark; ¹³Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, University of Kiel, Kiel, Germany; ¹⁴Department of Internal Medicine and Hemato-oncology, Faculty of Hospital Brno and Babak Research Institute, Faculty of Medicine, Masaryk University, Brno-město, Czech Republic; ¹⁵Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark;
Department of Hematology, Instituto Português de Oncologia, Lisbon, Portugal; Department of Hematology and Oncology, University Medical Center, Hamburg, Germany; Malignant Hematology and Stem Cell Transplantation Service, Alfred Hospital, Victoria, Australia; Department of Hematology, Ankara University, Ankara, Turkey; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany; and Department of Hematology, University Hospital Rotterdam, Rotterdam, Netherlands

Correspondence: Antonio Palumbo, Myeloma Unit, Division of Hematology, University of Torino, AOU S. Giovanni Battista, Torino, Italy; e-mail: appalumbo@yahoo.com

Tel.: +39 01 1663 5814
Fax: +39 01 1696 3737
Abstract

The majority of patients with newly diagnosed multiple myeloma (MM) are aged >65 years with 30% aged >75 years. Many elderly patients are also vulnerable due to comorbidities that complicate the management of MM. The prevalence of MM is expected to rise over time due to an aging population. Most elderly MM patients are ineligible for autologous transplantation and the standard treatment has, until recently, been melphalan plus prednisone. The introduction of novel agents, such as thalidomide, bortezomib and lenalidomide, has improved outcomes; however, elderly MM patients are more susceptible to side effects and are often unable to tolerate full drug doses. For these patients, lower-dose-intensity regimens improve the safety profile and thus optimize treatment outcome. Further research into the best treatment strategies for vulnerable elderly patients is urgently needed. Appropriate screening for vulnerability and an assessment of cardiac, pulmonary, renal, hepatic and neurological function, as well as age >75 years, at the start of therapy allows treatment strategies to be individualized and drug doses to be tailored to improve tolerability and optimize efficacy. Similarly, occurrence of serious non-hematologic adverse events during treatment should be carefully taken into account to adjust doses and optimize outcomes.
Introduction

Multiple myeloma (MM) is a malignant disease characterized by uncontrolled plasma tumor cell proliferation, driven by intrinsic chromosomal abnormalities and extrinsic stromal cell support, together with the presence of monoclonal protein in the blood and/or urine.\(^1,2\) Typical clinical presentation at diagnosis includes anemia (commonly presenting as fatigue), skeletal lesions (presenting as bone pain), renal impairment, and hypercalcemia. In Western countries, the annual age-adjusted incidence of MM is 5.6 cases per 100 000 people. The median patient age at diagnosis is approximately 70 years; only 37% of newly-diagnosed patients are aged <65 years, 26% are aged 65-74 years, and 37% are aged ≥75 years.\(^3\) The annual prevalence of MM in patients aged 65-74 years is approximately 31 cases per 100,000 people, and it increases to 46 cases per 100,000 people in patients aged ≥75 years. Furthermore, the number of elderly patients with MM is likely to increase due to the improved survival times that are associated with novel agents coupled with the increasing life-expectancy of the general population.

In recent years, the introduction of novel agents such as thalidomide, lenalidomide and the proteasome inhibitor bortezomib, which are associated with high-dose therapy and autologous stem-cell transplantation in young patients and standard chemotherapy in elderly patients, has changed the management of myeloma and extended overall survival (OS) times.\(^4-7\) An estimate of the 5-year relative survival of patients with MM in the United States from 1990-1992 to 2002-2004 reported a significant survival increase from 29% to 35%. More substantial increases were seen in patients aged <50 years (5-year relative survival from 45% to 57%) and those aged 50-59 years (5-year relative survival from 39% to 48%). By contrast, increases were much less pronounced in patients aged 60-69 years (5-year relative survival from 31% to 36%), and no improvement was seen in patients aged >70 years (5-year relative survival from 27% to 29%) (Figure 1).\(^3,5,6\) Notably, similar results were observed taking into account life expectancy with respect to age, sex and era of diagnosis. In a large population-based cohort study on 14,381 MM patients diagnosed in Sweden from 1973 to 2003, relative survival ratios, defined as the ratio of the observed survival divided by the expected survival, were computed as measures of survival. The 5-
year relative survival ratios improved significantly over the time but the improvement was confined to patients <70 years.4

Many patients aged ≥75 years are vulnerable due to their comorbid conditions that complicate the presentation and management of MM. Personalized therapy utilizing dose-adjusted regimens is, therefore, urgently needed for these patients. Vulnerable elderly patients are underrepresented in clinical trials8 and this population is not well studied, despite the fact that the majority of MM diagnoses and related mortality occurs in individuals aged >65 years. Further research into the best treatment strategies for vulnerable elderly patients with MM is therefore required, including an improved definition of clinical vulnerability in the elderly. This review discusses the impact of age and vulnerability on outcomes in MM patients, specifically focusing on the effect of these factors on treatment regimens in elderly patients.

**Impact of age on multiple myeloma prognosis and response to treatment**

Aging is associated with an increased risk of developing malignancies and the majority of cancer diagnoses and deaths occur in people aged >65 years.3 The global population is rapidly aging, and the number of individuals aged ≥65 years is expected to double between 2000 and 2030. Cancer types for which the highest percentage increase in incidence is expected between 2010 to 2030 are stomach (67%), liver (59%), MM (57%), prostate (55%), pancreatic (55%), bladder (54%), lung (52%), and colorectal (52%).9

Myeloma biology may differ by age at presentation. Ludwig et al analyzed the associations between the presenting features and survival times in 1,689 patients with newly diagnosed (ND) MM aged <50 years, compared with 8,860 patients aged >50 years. Younger patients were identified as having more favorable prognostic features, such as International Staging System and Durie-Salmon stages, and fewer adverse prognostic factors including elevated C-reactive protein, low hemoglobin, increased serum creatinine, and poor performance status. Younger patients had a significantly longer median survival time than those in the older cohort (5.2 years vs 3.7 years, respectively; \( P<.001 \)). After adjusting for MM-
unrelated mortality, lower International Staging System stage and other favorable prognostic features seem to account for the significantly longer survival of younger MM patients.\textsuperscript{10}

There are several factors that may underlie the impact of age on patient prognosis. The human aging process is associated with a gradual, progressive decrease in physiological reserve. Changes in body composition occur with age (there is a reduction in muscle mass, an increase in body fat, and a reduction in intracellular water levels) and all these changes may impact drug metabolism and distribution, but are not considered to have a major impact on cancer therapies. More importantly, however, are the age-related changes that occur in organ function. Aging is associated with clinically-significant reductions in renal function, gastric function, hepatic mass and blood flow, bone marrow status, and cardiovascular function in elderly patients.\textsuperscript{11-14} All of these changes may affect the pharmacokinetics and pharmacodynamics of drugs, altering clinical efficacy and potentially increasing toxicity. Age-related organ function and metabolic changes can, therefore, contribute to the poor tolerability of cancer treatments seen in elderly patients due to an increase in treatment-related adverse events (AEs). Reduced tolerability and reduced dose-intensity lead to the poorer outcomes observed in elderly cancer patients.

\textbf{The impact of vulnerability on cancer outcome in elderly patients}

Traditionally, the Karnofsky Performance scale or the World Health Organization scores are used to determine the fitness of cancer patients, but the role of performance status as unique marker of functional status needs to be revised. In elderly patients with or without cancer, three terms are commonly used interchangeably to describe vulnerable adults: frailty; comorbidity (or multiple chronic conditions); and disability. However, in geriatric medicine, there is a growing consensus that these are distinct clinical entities that are causally related. Frailty, comorbidity, and disability all occur individually and commonly among elderly patients, and each of these factors has clinical importance. Moreover, it is becoming increasingly clear that these three factors are interrelated and have a cumulative effect on the health and prognosis of elderly patients (Figure 2). The use of score tables established in geriatric medicine provides additional information to performance status: 9\% to 38\% of elderly patients with good performance status
(<2) were partially or fully dependent on others to carry out ordinary activities, such as household tasks and personal care.\textsuperscript{15,16}

\textbf{Frailty}

Frailty is a distinct entity recognized by clinicians, with many possible manifestations and no single symptom or sign that is itself sufficient or essential for a diagnosis.\textsuperscript{17} A phenotype of the clinically frail elderly adult was recently defined, based on the presence of a critical mass of \(\geq 3\) core elements of frailty: weakness; poor endurance; weight loss; low physical activity; and slow gait speed. The presence of frailty has been identified as an independent predictor of disability and other adverse outcomes in elderly adults.\textsuperscript{18} The differing degrees of frailty are outlined in Table 1.

\textbf{Comorbidity}

The formal definition of comorbidity is the concurrent presence of two or more medically diagnosed diseases in the same individual, with the diagnosis of each contributing disease based on established, widely recognized criteria.\textsuperscript{17} Many prognostic indices for the elderly that incorporate age and/or comorbidity are available;\textsuperscript{19-21} the Charlson comorbidity index is the one most frequently used in cancer patients.\textsuperscript{19,22} However, this is complex and a more simple score index for comorbidities in MM is needed. The Charlson index is a summary measure of 19 comorbid conditions weighted 1-6 corresponding to disease severity. This gives a total score ranging from 0-37. It can be adapted to account for increasing age, adding 1 point to the score for each decade over the age of 50 years. With this index, the relative risk of death that can be attributed to an increase of 1 point in the comorbidity score is equivalent to an additional decade of age.\textsuperscript{19} With aging, the incidence of comorbid conditions increases markedly, largely because the frequency of individual chronic conditions rises with age. As a result, 35\% of men and 45\% of women aged 60-69 years in the US have \(\geq 2\) comorbid conditions; this percentage increases dramatically to 53\% of men and 70\% of women by age 80 years.\textsuperscript{23} Comorbidity is associated with polymedication and increased risk of drug interactions.
**Disability**

Disability (which can include both physical and mental impairments or limitations) can be defined as difficulty or dependency in carrying out activities essential to independent living, including both essential personal care and household tasks, and activities that are important to maintain an individuals’ quality of life. Physical disability is common among elderly adults and is more common in elderly women than men. The major causes of physical disability in the elderly are chronic diseases such as cardiovascular disease, stroke, arthritis, and, in myeloma patients, orthopedic problems plus pain, highlighting the interrelationship between disability and comorbidity. The incidence of disability rises steadily with age among those aged ≥65 years. Of community-dwelling adults, 20-30% of those aged >70 years report some disability in mobility, tasks essential to household management (eg, shopping, meal preparation, managing money), and basic self-care tasks (eg, washing, dressing, eating). Disability, independent of its causes, is associated with a higher risk of mortality; disabled adults are more likely to become hospitalized.

**The impact of comorbidity on cancer outcomes**

No data are currently available on the impact of vulnerability on outcomes in MM patients, but the issues relating to comorbidity and cancer treatment are discussed in the following section in relation to elderly cancer patients in general.

An observational cohort study of 17,712 patients receiving treatment for multiple cancer types suggested that the severity of comorbidities affected survival outcomes in a progressive manner, independent of cancer stage. This observation was supported by several studies where comorbidities were associated with a higher risk of mortality.

Comorbid conditions have rarely been systematically studied among hematological patients. However, a large population-based study of 1,708 patients with myelodysplastic syndromes (MDS) demonstrated that those patients with MDS and comorbid conditions had a significantly higher risk of death than those without comorbidities. The risk was found to increase with an increasing number of
comorbid conditions and, therefore, a higher Charlson score (hazard ratio [HR] for death = 1.19 for patients with a Charlson index of 1-2; and HR = 1.77 for patients with a Charlson index ≥ 3). Wang et al also reported that MDS patients with congestive heart failure or chronic obstructive pulmonary disease have significantly shorter survival times than their counterparts without those conditions, whereas diabetes does not appear to have an impact on survival in patients with MDS. Another study involving 998 elderly patients with acute leukemia or MDS supported these findings on the impact of comorbidity and identified several factors associated with poor outcome, including age ≥ 75 years, a longer duration of prior hematological disorder, and abnormal organ function.

**The relationship between age and vulnerability in multiple myeloma**

Although there is evidence for the separate prognostic importance of age, comorbidity, frailty, and disability for health outcomes, it is also important to note that many patients have two or more of these factors, and that this has a cumulative, adverse impact on their prognosis. The frequently used Charlson index has been described above, but another prognostic index has also been successfully developed for assessment of post-hospitalization mortality risk in elderly patients aged >70 years. This utilizes the combined impact of age, physical disability (determined by levels of dependency in activities in daily living), and levels of comorbidity.

Studies in geriatric oncology populations, including patients with prostate, lung and ovarian cancer, have also demonstrated the combined effects of age, comorbidity, frailty, and disability on patient prognosis. In a large prospective trial involving 427 patients with cancer (over half of whom had hematologic malignancies), age, severe comorbidities, functional impairment, and tumor type were all found to be independently related to shorter survival times. Similarly, in the setting of colorectal carcinoma, a model developed as part of a Surveillance, Epidemiology, and End Results (SEER) registry review utilized comorbidity and age in addition to gender and disease stage in a model to predict early mortality. The number of comorbid conditions a patient had was found to significantly predict early mortality.
In hematologic oncology, data on the combined impact of vulnerability and age are limited. As discussed earlier, a series of MDS patients aged ≥66 years identified comorbidity (assessed using the Charlson comorbidity index) as a significant predictor of mortality. A comorbidity index developed specifically for patients undergoing hematopoietic cell transplantation was found to have high sensitivity and was effective in predicting outcomes in patients with acute myeloid leukemia.\textsuperscript{42} A retrospective analysis of 968 adults with acute myeloid leukemia was designed to assess the biology of the condition change with patient age. In this analysis, elderly patients presented more frequently with poorer performance status and with unfavorable cytogenetics. In particular, the combination of poor performance status and advanced age identified a group of patients who were highly likely to die within 30 days of starting induction therapy.\textsuperscript{43} Unfortunately, however, similar data addressing the prognostic impact of age and vulnerability in patients with MM are not currently available.

**Clinical treatment of elderly patients with multiple myeloma**

*Standard treatment regimens for newly-diagnosed elderly patients (≥65 years)*

NDMM patients aged >65 years are generally considered ineligible for autologous stem-cell transplantation as they are physically unable to withstand toxicity of the procedure, although this considerably differs from patient to patient, and melphalan dose reduction may allow even patients >70 years to undergo transplantation. Standard frontline treatment for elderly, transplant-ineligible patients has, until recently, been the alkylating agent melphalan in combination with prednisone (MP). This regimen is well tolerated in vulnerable elderly patients and is associated with good response rates and survival outcomes that are comparable with other conventional combinations of chemotherapy.\textsuperscript{44,45} However, the availability of novel agents, including the immunomodulatory agents thalidomide and lenalidomide, and the proteasome inhibitor bortezomib, has led to the development of new treatment options for NDMM patients.\textsuperscript{46} These novel agents can be used in combination with MP as well as in other treatment combinations, such as lenalidomide with low-dose dexamethasone.\textsuperscript{47-51}
Melphalan plus prednisone versus combination melphalan, prednisone, and thalidomide

Six randomized studies have compared the efficacy and safety of the standard MP regimen with the new combination of MP plus thalidomide (MPT).48-50,52-55 These studies reported improved clinical response rates and a longer progression-free survival (PFS) associated with MPT compared with MP, but the effect of MPT on OS was unclear (Table 2).47-58 However, a recent meta-analysis of data from 1,682 patients in the six randomized studies of MPT versus MP has confirmed a significant improvement in PFS and a trend towards significant improvement in OS when thalidomide is added to MP as a front-line treatment in elderly NDMM patients.59 MPT was associated with better 1-year overall response rate (ORR; 59% with MPT vs 37% with MP) and prolonged PFS (median, 20 months with MPT vs 15 months with MP; \(P<.0001\)). The thalidomide regimen also led to a 17% risk reduction of death compared with MP (HR=0.83; 95% confidence interval [CI], 0.73-0.94; \(P=.004\)) and an increased median OS time of 6.6 months.59 This improvement was less pronounced in patients aged \(\geq75\) years. In the Nordic study, the median PFS of these patients was shorter compared with patients aged 65-74 years (10 months with MPT vs 6 months with MP) and no improvement was observed in OS.52 Similar results have been reported in the Myeloma IX study using thalidomide in combination with the alternative alkylating agent, cyclophosphamide, and steroid, dexamethasone.60

The most common grade 3-4 non-hematologic AEs associated with MPT were peripheral neuropathy (6-23%), thromboembolism (3-12%), infections (10-13%), cardiac complications (2-7%), and gastrointestinal events (about 5%). Thalidomide discontinuation due to AEs varied from 33-45%.61 Some studies reported a doubling of early toxic deaths among patients aged \(\geq75\) years and no favorable effect of thalidomide on OS in patients with higher World Health Organization performance status.52,54

Melphalan plus prednisone versus combination bortezomib, melphalan, and prednisone

Bortezomib is effective and well tolerated in patients with relapsed or refractory MM.62,63 The clinical value of adding bortezomib to the standard MP regimen (VMP) was explored in the Velcade as Initial Standard Therapy (VISTA) study.47,56 ORR in patients treated with VMP was higher compared with the
MP regimen (80% vs 56%, respectively; \( P<.001 \)). Similarly, a higher proportion of these patients achieved a complete response compared with the MP regimen (30% vs 4%, respectively; \( P<.001 \)); time-to-progression was also prolonged (24 vs 16.6 months, respectively; \( P<.001 \)). Importantly, OS was significantly extended in the VMP regimen (HR=0.61; \( P=.008 \)). These results have been confirmed by an extended follow-up of the VISTA study. After a median follow-up of 36.7 months the risk of death associated with the VMP regimen was 35% lower than with MP (HR=0.653; \( P<.001 \)). Median survival time was not reached in the VMP regimen compared with 43 months in the MP regimen.\(^4\)\(^7\) Also in the VISTA study, outcomes were worse in patients aged ≥75 years; within the VMP group, the 3-year OS was longer among patients aged <75 years (74%) compared with patients aged ≥75 years (55%).\(^5\)\(^6\) Similar results both for efficacy and safety were observed in a US community-based phase 3b study comparing VMP with bortezomib-dexamethasone and with bortezomib-thalidomide-dexamethasone.\(^6\)\(^4\)

The incidence of any grade 3-4 hematologic and non-hematologic AEs with VMP was 91%, leading to a bortezomib discontinuation rate of 34%. Neutropenia (40%) is the main AE associated with VMP, followed by thrombocytopenia (37%), peripheral neuropathy (14%), infections (10%), and gastrointestinal events (7%).\(^4\)\(^7\),\(^5\)\(^6\) The recent update of the VISTA study showed that the rate of severe AEs was higher in the first four cycles when a twice-weekly bortezomib schedule was administered; it was lower during the last five cycles when the lower-dose-intensity once-weekly bortezomib schedule was administered.\(^5\)\(^6\) Two subsequent studies showed that a once-weekly schedule significantly reduced the incidence of any grade 3-4 hematologic and non-hematologic AEs, in particular peripheral neuropathy (7-8%), as well as the rate of discontinuation due to toxicity.\(^6\)\(^5\),\(^6\) This improvement in safety was obtained without negatively impacting on outcomes because although the cumulative planned-dose was lower in the once-weekly group (46.8 vs 67.6 mg/m\(^2\)), the cumulative delivered-dose of bortezomib was similar in the two groups (39.4 mg/m\(^2\) in the once-weekly and 40.1 mg/m\(^2\) in the twice-weekly group; Table 3).\(^4\)\(^7\),\(^5\)\(^1\),\(^5\)\(^7\),\(^6\)\(^5\),\(^6\)
Melphalan plus prednisone versus combination melphalan, prednisone, and lenalidomide followed by continuous lenalidomide treatment

The IMiD® immunomodulatory compound lenalidomide has demonstrated efficacy in patients with relapsed or refractory MM, and has also been evaluated in combination with MP as a frontline treatment for NDMM patients.67,68 Initial results of the randomized trial comparing the addition of lenalidomide to MP followed by lenalidomide maintenance treatment (MPR-R) with standard MP (MM-015 study) indicate that MPR-R was superior to the standard MP regimen.58 The ORR was significantly higher with MPR-R compared with MP (77% vs 50%, respectively; \(P<.001\)). Complete response rates were also significantly higher with MPR combination therapy (16% vs 4%; \(P<.001\)). After a median follow-up of 21 months, MPR-R led to gains on PFS and reduced the risk of disease progression by 58% compared with MP alone (HR=0.423; \(P<.001\)). Median PFS was 31 months in the MPR-R regimen compared with 14 months for MPR and 13 months for MP, the 2-year PFS was significantly higher in patients who received lenalidomide continuous therapy compared with fixed duration MP (55% vs 16%, respectively; \(P<.001\)). The importance of continuous lenalidomide therapy on outcomes is elucidated by a landmark analysis of PFS in patients completing induction therapy and proceeding onto maintenance therapy. This demonstrated a 75% reduced risk of disease progression with continuous lenalidomide therapy versus no treatment (\(P<.001; HR=0.245; 95\% CI, 0.126-0.476\)). However, no differences in OS have been reported, likely due to the short duration of follow-up to date, the administration of lenalidomide at relapse, and possibly more resistant relapses.58 Preliminary analysis indicates that outcomes may be worse in patients aged \(\geq 75\) years, possibly explained by the lower relative dose-intensity of MPR that these patients received during induction therapy. In patients aged 65-74 years, MPR alone was superior to MP in terms of PFS (HR=0.675; \(P=.030\)), but this advantage was not evident in patients aged \(\geq 75\) years. Hence, the MPR toxicity profile was excessive for frail patients and negatively affected efficacy. The main grade 3-4 hematologic and non-hematologic AEs associated with MPR were neutropenia (52-71%), thrombocytopenia (23-38%), infections (10%), and thromboembolism (5%).58,69 In the first 9 cycles of
therapy, the discontinuation rate due to AEs was 4% in the MP group among patients aged 65-74 years and 8% in patients aged ≥75 years. The discontinuation rate due to toxicity was 12% in the MPR or MPR-R group among patients aged 65-74 years, and 19% in patients aged ≥75 years. The cumulative dose intensity was similar in MP and MPR or MPR-R patients aged 65-74 years (97% and 88%, respectively), whereas it was reduced in patients aged ≥75 years (97% and 56%, respectively).58 These data clearly show that the intended dose-intensity is well maintained in the MP group, is adequate for the MPR regimens in patients aged 65-74 years, and is totally unmaintained in those aged ≥75 years. Thus, further dose reduction to keep the patient on therapy is needed.

**Lenalidomide and dexamethasone**

In NDMM patients, lenalidomide in combination with high-dose dexamethasone (RD) has been shown to improve PFS and ORR rates compared with high-dose dexamethasone monotherapy.70 However, RD was associated with an increased incidence of thromboembolic complications so an adapted regimen of lenalidomide with low-dose dexamethasone (Rd) was evaluated.51 ORR was lower with Rd (70%) compared with RD (81%). The higher response rates for the high-dose dexamethasone regimen did not translate into superior PFS (median, 25.3 months in the Rd group vs 19.1 months in the RD group). The Rd regimen was associated with significantly improved 1-year OS compared with RD (96% vs 87%, respectively; \( P=0.0002 \)) and treatment-related toxicity was also significantly reduced. Similar results were observed when the analysis was restricted to 248 patients who did not receive transplant.51 These data indicate that the Rd regimen is an effective regimen for newly diagnosed patients with acceptable toxicity. Although the advantages associated with Rd compared with RD were also confirmed in a subgroup of patients aged >70 years, inferior outcomes were observed in this subset of patients; the ORR was 74% with Rd and 75% with RD. Median PFS was 22 months in the low-dose dexamethasone group compared with 16 months in the high dose group, and OS was improved in the low-dose dexamethasone regimen (3-year OS, 73% in the Rd group vs 61% in the RD group).71
The incidence of any grade 3-4 non-hematologic AEs was 35% with Rd and 52% with RD, and the respective discontinuation rate due to AEs was 19% and 27%, respectively. Deep-vein thrombosis or pulmonary embolism were the most frequent toxicities, and were reported in 12% of patients in the Rd group and 26% in the RD group; infection was another common AE (9% with Rd and 16% with RD). The advantages of Rd over RD were more pronounced in patients aged >70 years due to the poor tolerability, higher toxicity profile, and higher mortality rate associated with the high-dose dexamethasone in this population. In these patients, the incidence of any grade 3-4 non-hematologic AE increased to 59% in the Rd regimen and 78% in the RD regimen. A phase II trial in relapsed/refractory patients showed that lower doses of lenalidomide (15 mg) plus low dose dexamethasone (40 mg weekly) significantly reduced the incidence of hematologic toxicities (from 15-30% to 2-13%), infections (from 20% to 8%), and thromboembolism (from 20% to 5%).

Evidence is now emerging that maintenance/continuous therapy with novel agents such as thalidomide, lenalidomide, or bortezomib is improving PFS with a potential to improve OS. However, in elderly patients it is particularly important to start treatment at a dose that can be tolerated over the long-term.

**Tolerability of novel antitymelyoma treatment in elderly patients**

Although the novel agents offer important improvements in survival for patients with MM, the incidence of grade 3-4 AEs are significantly higher with combination regimens based on novel agents than with traditional chemotherapy regimens (Table 3). This is reflected in the discontinuation rates due to AEs in regimens containing novel agents (13-45% across studies). Elderly patients with MM are more susceptible to AEs associated with treatments, with 42-53% of elderly patients experiencing grade 3-4 AEs in the early cycles of treatment with a novel agent.

Drug-related treatment complications are prevalent among elderly or vulnerable MM patients and may lead to premature treatment discontinuations or lower dose intensities. Therefore, to reduced treatment efficacy it is crucial that these are anticipated and managed accordingly. This highlights the
need for dosing strategies to improve the tolerability of treatment with the novel antimyeloma agents, especially during induction therapy, in vulnerable, elderly patients to allow for long-term treatment. Furthermore, the tolerability of treatment could be improved with supportive therapy, particularly in elderly patients. Granulocyte colony-stimulating factors decrease or prevent neutropenia. Aspirin or low-molecular-weight heparins should be used to decrease the risk of thromboembolic events when immunomodulatory compounds are given. Erythropoiesis-stimulating agents can be used to treat chemotherapy-associated anemia with iron supplements improving the effectiveness of treatment. Bone pain requires systemic analgesia, local measures, and chemotherapy. Local radiotherapy is effective for palliation of bone pain, and bisphosphonates can reduce new bone lesions, pathologic fractures, and hypercalcemia. Appropriate hydration, urine alkalinization, rapidly acting therapy for myeloma, and treatment of hypercalcemia, hyperuricemia and infections prevent further deterioration of renal function in patients with renal impairment.

In the context of treatment tolerability and individualized treatment strategies, it is also important to consider the management of elderly MM patients with relapsed, or relapsed and refractory disease. These patients are exposed to multiple sequential lines of treatment, which are likely to have a progressive weakening effect on their overall physical condition. Therefore, treatment strategies for elderly patients should have minimal cumulative toxicity across the lines of treatment. These should not exacerbate any pre-existing conditions such as peripheral neuropathy, which commonly develops as an adverse effect of treatment with thalidomide or bortezomib. Supportive therapies, dose adjustments, clinical vigilance, and patient education are important to minimize AEs and maintain compliance with antimyeloma treatment.

**Tailored therapy for the treatment of elderly multiple myeloma patients**

The age-related changes in physiology combined with comorbid conditions, disability, and/or frailty have important implications for the treatment of cancer patients. However, in MM patients treatment should not be withheld solely on the basis of age. A patient’s overall physical condition and organ function
should be assessed in order to determine their ability to tolerate treatment. Elderly NDMM patients should, therefore, be assessed for frailty, comorbidity, and disability. Cardiac performance, pulmonary and hepatic function, renal function (especially in elderly patients determined with creatinine clearance), and peripheral neuropathy should be evaluated. Based on the results of these tests it is possible to stratify patients into those suitable for full-dose therapy or combination drug treatment, and those requiring adjusted-dose treatment strategies (Table 4). We propose recommendations whereby patients with ≥1 risk factor (age ≥75 years, frailty, comorbidities, disability, or grade 3-4 non-hematologic AEs), should be considered for a reduced-dose treatment strategy. Patients without risk factors should be administered full-dose treatment.46,79 Recommended starting doses and dose-adjustments according to age groups and vulnerability status are presented in Table 4. When a grade 3 or 4 AE occurs during treatment, therapy should be discontinued until the toxicity has resolved, usually by the start of the next cycle, at which point treatment can be restarted at a lower dose (Table 4). Modifying drug doses at the start of treatment or to manage AEs is important as it improves tolerability. Treatment should be interrupted and changed in patients not responding after ≥3 cycles, whereas continuous long-term therapy beyond best response may be important for sustained disease control of the residual disease in MM.57,58,65

Conclusions

Advanced age and patient vulnerability have a significant and cumulative impact on survival outcomes and treatment efficacy in patients with cancer. In MM, elderly patients have a worse prognosis from initial diagnosis than those aged <65 years. Currently, the improvements in survival associated with the novel antmyeloma agents have not been observed in elderly patients.

No data are available that assess screening for vulnerability before choosing and starting therapy for MM. However, although no data are available specifically for patients with MM due to the underrepresentation in clinical trials of elderly adults and patients with comorbidities, it is reasonable to translate data on elderly general population to the MM population. We can, therefore, speculate that the continued poor prognosis of elderly MM patients may be attributable, at least in part, to physical
vulnerability and the impact that this has on patients’ ability to tolerate complex treatment regimens. It is, therefore, important to consider the age, physical condition, and comorbidity status for all elderly MM patients when planning treatment. Appropriate dose-adjustments or use of modified treatment regimens should be made accordingly in order to improve the tolerability of treatment. Well tolerated regimens are likely to reduce the need for treatment interruptions and thereby should optimize treatment efficacy.

Future trials should address the role of age, comorbidities, and geriatric assessment by stratifying MM patients into treatment groups at different risk of mortality. In addition to greater inclusion of vulnerable elderly patients in standard trial protocols, trials that address specific needs in elderly adults (eg, renal impairment) may also yield important insights. To promote the enrolment of elderly adults in clinical trials it may be necessary to relax standard protocol eligibility criteria by focusing on developing therapeutics suitable for patients with comorbid conditions. Clinical trials focused on optimizing MM treatment regimens for both fit and unfit elderly adults are urgently needed. The data from such trials, when available, will eventually lead to tailored, ‘personalized’ therapy for elderly MM patients and thereby improve OS in this large patient group.

Authorship

Contribution: A.P., S.B., H.L., M.A.D., J.B., M.V.M., L.R., M. Boccadoro, M.C., H.L., S.Z., E.T., F.D., C.D., P.G., M.G., R.H., H.E.J., F.L.D.C., O.S., A.S., M. Bek sac, G.M., H.E., J.F.S.M., and P.S. developed the consensus, provided critical review and edits to the manuscript, gave approval to the final manuscript, and significantly participated in the development of the consensus and writing of the manuscript.

Conflict-of-interest disclosure: A.P. has received honoraria from Celgene, Janssen-Cilag, Merck and Amgen, and served on the advisory board for Celgene and Janssen-Cilag; S.B. has received honoraria from Celgene, Janssen-Cilag, and Novartis and served on the advisory committee of Merck Sharp & Dohme; H.L. has received honoraria from and served on the advisory board for Celgene, and speakers bureau for Celgene and Ortho-Biotech; M.A.D. has received honoraria from Ortho-Biotech, Celgene and
Novartis; J.B. has received honoraria from Celgene and Janssen-Cilag; M.V.M. has received honoraria from Celgene, Janssen-Cilag, Millennium and Novartis; L.R. has received honoraria from Celgene and Janssen-Cilag; M. Boccadoro has received research support from, and served on the consultancy and the scientific advisory board from Celgene and Janssen-Cilag; M.C. has received honoraria and served on speakers’ bureaus for Janssen-Cilag, Millennium Pharmaceuticals, Celgene, and Novartis, and has been a consultant for Janssen-Cilag and Millennium Pharmaceuticals; H.L. has been a consultant for Celgene and Genmab; S.Z. has received honoraria from and served on the advisory board for Celgene and Janssen-Cilag; E.T. has received honoraria from and served on the advisory board for Novartis, Amgen, Celgene and Janssen-Cilag; F.D. has served on the advisory board for Celgene, Novartis, and Ortho-Biotech, and received travel support from Celgene and Ortho-Biotech; P.G. served as chairman of data safety and on the monitoring committee for BioInvent, and served on the speakers bureau for Celgene, Nordic Cancer Union, Amgen, Janssen-Cilag, and Nordpharma; R.H. has received honoraria from Celgene, Janssen-Cilag, MDS, and educational grants from Celgene, Janssen-Cilag; F.L.D.C. has been a consultant and received honoraria from Celgene, Janssen-Cilag, Merck Sharp & Dohme and OM Pharma; O.S. has received honoraria from Celgene, Janssen-Cilag, Amgen, Novartis, and research funding from Janssen-Cilag and Novartis; M. Beksac has received honoraria from Celgene and Janssen-Cilag; G.M. has been a consultant and served on the advisory board for Celgene, Johnson & Johnson and Lilly; H.E. has served on the advisory board for Celgene, Novartis and Janssen-Cilag; J.F.S.M. has served on the advisory board for Millennium, Celgene and Johnson & Johnson; P.S. has received research support from Celgene, Janssen-Cilag, Onyx, and served on the advisory board for Celgene, Janssen-Cilag, Millennium and Onyx.

All the other authors declare no competing conflicts of interest.

Acknowledgements: the authors thank the editorial assistant Giorgio Schirripa
References


60. Morgan GJ, Davies FE, Gregory WM, et al. The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS. *Blood*. 2009;114. Abstract 353.


Table 1. Levels of frailty and disability in elderly patients and related description.

<table>
<thead>
<tr>
<th>Frailty grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very fit</td>
<td>Active, energetic patients, who exercise regularly or occasionally</td>
</tr>
<tr>
<td>Moderately fit</td>
<td>Patients not regularly active beyond routinely walking</td>
</tr>
<tr>
<td>Vulnerable</td>
<td>Patients who can perform limited activities but yet do not need help from other people</td>
</tr>
<tr>
<td>Mildly frail</td>
<td>Patients who need help for household tasks (shopping, walking several blocks, managing their finance, and medications)</td>
</tr>
<tr>
<td>Moderately frail</td>
<td>Patients who need partial help for their personal care (dressing, bathing, toileting, eating)</td>
</tr>
<tr>
<td>Severely frail</td>
<td>Patients completely dependent from other people for their personal care</td>
</tr>
<tr>
<td>Regimen</td>
<td>Median age, years</td>
</tr>
<tr>
<td>---------</td>
<td>------------------</td>
</tr>
<tr>
<td>MPT⁴⁸</td>
<td>69</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>MPT⁴⁹,⁵⁰</td>
<td>72</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>MPT⁵²</td>
<td>72</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>MPT⁵³</td>
<td>78</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>MPT⁵⁴</td>
<td>74</td>
</tr>
<tr>
<td>Regimen</td>
<td>Median age, years</td>
</tr>
<tr>
<td>---------</td>
<td>------------------</td>
</tr>
</tbody>
</table>
| MPT$^{55}$ | 69 | P: 100mg/day days 1-4 for 6-week cycles until plateau 
T: 400 mg/day until plateau, reduced to 200 mg/day until progression | 9 | 21$^\dagger$ | 26 | 16 | NA |
| VMP$^{57,56}$ | 71 | V: 1.3 mg/m$^2$ days 1, 4, 8, 11, 22, 25, 29, and 32 for first four 6-week cycles; days 1, 8, 15, and 22 for subsequent five 6-week cycles 
M: 9 mg/m$^2$ days 1-4 
P: 60 mg/m$^2$ days 1-4 | 30 | NA | Not reached | 34 | 91$^*$ |
<p>| VMP$^{57}$ | 71 | V: 1.3 mg/m$^2$ days 1, 4, 8, 11, 22, 25, 29, and 32 | 24 | 23 | Not | 17 | 33 |</p>
<table>
<thead>
<tr>
<th>Regimen</th>
<th>Median age, years</th>
<th>Dosing</th>
<th>CR rate, %</th>
<th>Median PFS, months</th>
<th>Median OS, months</th>
<th>Discontinuation rate, %</th>
<th>Non-hematologic grade 3-4 AEs, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPR-R\textsuperscript{58}</td>
<td>NA</td>
<td>M: 0.18 mg/kg days 1-4</td>
<td>16</td>
<td>31</td>
<td>Not</td>
<td>14\textsuperscript{1}</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P: 2 mg/kg days 1-4</td>
<td>reached</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>R: 10 mg days 1-21 for nine 4-week cycles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>R: 10 mg/day until relapse</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rd\textsuperscript{51}</td>
<td>66</td>
<td>R: 25 mg days 1-21</td>
<td>4</td>
<td>25</td>
<td>Not</td>
<td>19</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D: 40 mg days 1-4, 9-12, 17-20</td>
<td>reached</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>or</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>d: 40 mg days 1, 8, 15, 22 in 4-week cycles</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VMPT\textsuperscript{57}</td>
<td>71</td>
<td>V: 1.3 mg/m\textsuperscript{2} days 1, 4, 8, 11, 22, 25, 29, and 32 during cycles 1-4; days 1, 8, 15, and</td>
<td>38</td>
<td>Not</td>
<td>Not</td>
<td>23</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td></td>
<td>32 during cycles 1-4; days 1, 8, 15, and</td>
<td>reached</td>
<td>reached</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{1}Discontinuation rate reached 16 months in the MPR-R study.
<table>
<thead>
<tr>
<th>Regimen</th>
<th>Median age, years</th>
<th>Dosing</th>
<th>CR rate, %</th>
<th>Median PFS, months</th>
<th>Median OS, months</th>
<th>Discontinuation rate, %</th>
<th>Non-hematologic grade 3-4 AEs, %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22 during cycles 5-9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

M: 9 mg/m² days 1-4

P: 60 mg/m² days 1-4

T: 50 mg daily for nine 6-week cycles

CR indicates complete response; PFS, progression-free survival; OS, overall survival; AE, adverse event; MPR-R, melphalan, prednisone, and lenalidomide followed by lenalidomide maintenance; NA, not available; Rd, lenalidomide plus low-dose dexamethasone; VMP, bortezomib, melphalan, and prednisone; VMPT, bortezomib, melphalan, prednisone, and thalidomide.

*Both hematologic and non-hematologic AEs.

†CR plus very good partial response (CR alone not available).

‡Event-free survival.

§Disease-free survival.

¶Including both patients who received lenalidomide maintenance and those who did not.
Table 3. Outcome of newly diagnosed patients treated with full-dose or reduced-dose regimens

<table>
<thead>
<tr>
<th></th>
<th>Any grade 3-4 AEs, %</th>
<th>Discontinuation rate due to toxicity, %</th>
<th>PFS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Standard dose therapies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VMP$^{57}$</td>
<td>91</td>
<td>3</td>
<td>50% at 2 years</td>
<td>68% at 3 years</td>
</tr>
<tr>
<td>RD$^{51}$</td>
<td>52</td>
<td>27%</td>
<td>48% at 2 years</td>
<td>78% at 2 years</td>
</tr>
<tr>
<td><strong>Lower dose therapies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VMP$^{57,65}$</td>
<td>51</td>
<td>12-17</td>
<td>46-50% at 3 years</td>
<td>74-87% at 3 years</td>
</tr>
<tr>
<td>Rd$^{51}$</td>
<td>35</td>
<td>19</td>
<td>52% at 2 years</td>
<td>88% at 2 years</td>
</tr>
</tbody>
</table>

AE indicates adverse event; PFS, progression-free survival; OS, overall survival; RD lenalidomide plus high-dose dexamethasone; Rd, lenalidomide plus low-dose dexamethasone.
Table 4. Treatment algorithm for elderly frail patients (adapted from Palumbo A and Anderson K\textsuperscript{46}).

<table>
<thead>
<tr>
<th>Risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Age over 75 years</td>
</tr>
<tr>
<td>• Mild, moderate or severe frailty:</td>
</tr>
<tr>
<td>patients needing help for household tasks and personal care*</td>
</tr>
<tr>
<td>• Comorbidities:</td>
</tr>
<tr>
<td>cardiac dysfunction</td>
</tr>
<tr>
<td>pulmonary dysfunction</td>
</tr>
<tr>
<td>hepatic dysfunction</td>
</tr>
<tr>
<td>renal dysfunction</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>GO-GO</strong></th>
<th><strong>MODERATE-GO</strong></th>
<th><strong>SLOW-GO</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>No risk factors</td>
<td>At least one risk factor</td>
<td>At least one risk factor plus occurrence of grade 3-4 non-hematologic AE</td>
</tr>
<tr>
<td>DOSE LEVEL 0</td>
<td>DOSE LEVEL −1</td>
<td>DOSE LEVEL −2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Agent</th>
<th>DOSE LEVEL 0</th>
<th>DOSE LEVEL −1</th>
<th>DOSE LEVEL −2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone</td>
<td>40 mg/d d 1,8,15,22 / 4 wks</td>
<td>20 mg/d d 1,8,15,22 / 4 wks</td>
<td>10 mg/d d 1,8,15,22 / 4 wks</td>
</tr>
<tr>
<td>Melphalan</td>
<td>0.25 mg/kg or 9 mg/m\textsuperscript{2} d 1-4 / 4-6 wks</td>
<td>0.18 mg/kg or 7.5 mg/m\textsuperscript{2} d 1-4 / 4-6 wks</td>
<td>0.13 mg/kg or 5 mg/m\textsuperscript{2} d 1-4 / 4-6 wks</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>100 mg/d</td>
<td>50 mg/d</td>
<td>50 mg qod</td>
</tr>
<tr>
<td>Lenalidomide</td>
<td>25 mg/d d 1-21 / 4 wks</td>
<td>15 mg/d d 1-21 / 4 wks</td>
<td>10 mg/d d 1-21 / 4 wks</td>
</tr>
<tr>
<td>Bortezomib</td>
<td>1.3 mg/m\textsuperscript{2} twice weekly d 1,4,8,11 / 3 wks</td>
<td>1.3 mg/m\textsuperscript{2} once weekly d 1,8,15,22 / 5 wks</td>
<td>1.0 mg/m\textsuperscript{2} once weekly d 1,8,15,22 / 5 wks</td>
</tr>
<tr>
<td>Prednisone</td>
<td>60 mg/m\textsuperscript{2} d 1-4 or 50 mg qod</td>
<td>30 mg/m\textsuperscript{2} d 1-4 or 25 mg qod</td>
<td>15 mg/m\textsuperscript{2} d 1-4 or 12.5 mg qod</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>100 mg/d d1-21 / 4 wks or 300 mg/m\textsuperscript{2}/d d 1,8,15 / 4 wks</td>
<td>50 mg/d d 1-21 / 4 wks or 150 mg/m\textsuperscript{2}/d D 1,8,15 / 4 wks</td>
<td>50 mg qod d 1-21 / 4 wks or 75 mg/m\textsuperscript{2}/d d 1,8,15 / 4 wks</td>
</tr>
</tbody>
</table>

* Details reported in Table 1

AE denotes adverse event; d, day; wk, week; qod, every other day
Figure legends

Figure 1. Five-year relative survival rates according to the year of diagnosis and the patients’ age at diagnosis. Survival rates have increased over the past 35-years in all patient age groups, a trend attributed to the impact of novel agents such as thalidomide, bortezomib, and lenalidomide; however, significant increases in survival have only been observed in patients aged <65 years at initial diagnosis.³

Figure 2. The interrelationship between the three components of vulnerability (comorbidity, frailty, and disability) and the major healthcare implications associated with each factor.
Figure 1
Figure 2

Assessment for vulnerability in newly diagnosed MM patients

- Presence of chronic diseases or conditions
  - Comorbidity
  - Actions:
    - Consider drug interactions
    - Incompatibility of treatment
    - Minimize risk of frailty
    - Minimize risk of disability

- Limits in the major life activities due to physical or mental impairment
  - Disability
  - Actions:
    - Need for supportive service
    - Minimize risk of mortality
    - Decrease risk of hospitalization

- Weight loss, fatigue, low activity, slow motor balance and gait
  - Frailty
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

Antonio Palumbo, Sara Bringhen, Heinz Ludwig, Meletios A. Dimopoulos, Joan Bladé, Maria V. Mateos, Laura Rosiñol, Mario Boccadoro, Michele Cavo, Henk Lokhorst, Sonja Zweegman, Evangelos Terpos, Faith Davies, Christoph Driessen, Peter Gimsing, Martin Gramatzki, Roman Hájek, Hans E. Johnsen, Fernando Leal Da Costa, Orhan Sezer, Andrew Spencer, Meral Bekşac, Gareth Morgan, Hermann Einsele, Jesus F. San Miguel and Pieter Sonneveld

Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.